Ultragenyx Pharmaceutical, Inc. (RARE)
23.70
+0.33
(+1.41%)
USD |
NASDAQ |
May 21, 16:00
23.70
0.00 (0.00%)
After-Hours: 19:59
Ultragenyx Pharmaceutical Research and Development Expense (TTM) : 736.94M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 11.48M |
| BioMarin Pharmaceutical, Inc. | 721.03M |
| Regeneron Pharmaceuticals, Inc. | 5.526B |
| Xencor, Inc. | 245.52M |
| REGENXBIO, Inc. | 217.03M |